Janssen Wins EU Fast-Track Status For CAR-T Therapy Cilta-Cel
Filing Of Potential Multiple Myeloma Treatment Planned For H1
Three requests for the accelerated assessment of planned EU marketing applications were considered by the European Medicines Agency last month.
You may also be interested in...
One out of seven requests for the accelerated assessment of planned EU marketing authorization applications is known to have been granted this year to date.
Just three of the 13 applications that the European Medicines Agency most recently reviewed for entry onto its priority medicines scheme made the grade.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.